These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 20524296)
1. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC. Pavlakis M Clin Transpl; 2009; ():343-5. PubMed ID: 20524296 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection. Al Meshari K Clin Transpl; 2009; ():385-6. PubMed ID: 20524302 [No Abstract] [Full Text] [Related]
5. Bortezomib rescue in refractory acute humoral rejection--report of a case. Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V Clin Transpl; 2009; ():431-2. PubMed ID: 20524310 [No Abstract] [Full Text] [Related]
6. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series. Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J Clin Transpl; 2009; ():351-8. PubMed ID: 20527073 [TBL] [Abstract][Full Text] [Related]
7. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib. Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA Clin Transpl; 2009; ():377-84. PubMed ID: 20524301 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib for acute humoral rejection in two repeat transplant recipients. Hardinger KL; Alford K; Murillo D Clin Transpl; 2009; ():479-83. PubMed ID: 20524319 [TBL] [Abstract][Full Text] [Related]
9. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports. Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C Clin Transpl; 2009; ():433-8. PubMed ID: 20524311 [TBL] [Abstract][Full Text] [Related]
13. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
14. Rescue therapy for early antibody mediated rejection with a proteasome inhibitor: a case report. Manitpisitkul W; Wilson N; Cooper M; Gurk-Turner C; Hurley H; Rasetto F; KuKuruga D; Barth RN; Philosophe B Clin Transpl; 2009; ():461-3. PubMed ID: 20524315 [No Abstract] [Full Text] [Related]
15. Use of bortezomib for prevention and treatment of rejection in sensitized patients. Hartono C; Lubetzky M; Aull MJ; Saal S; Figueiro J; Kapur S; Dadhania D Clin Transpl; 2009; ():499-503. PubMed ID: 20524323 [TBL] [Abstract][Full Text] [Related]
16. Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line? Lee I; Constantinescu S; Gillespie A; Swami A; Birkenbach M; Leech S; Silva P; Karachristos A; Daller JA; Sifontis NM Clin Transpl; 2009; ():425-9. PubMed ID: 20524309 [No Abstract] [Full Text] [Related]
17. Proteasome inhibition for antibody-mediated rejection. Everly JJ; Walsh RC; Alloway RR; Woodle ES Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989 [TBL] [Abstract][Full Text] [Related]
18. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection. Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D Clin Transpl; 2011; ():381-7. PubMed ID: 22755435 [TBL] [Abstract][Full Text] [Related]
19. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Wahrmann M; Haidinger M; Körmöczi GF; Weichhart T; Säemann MD; Geyeregger R; Kikić Z; Prikoszovich T; Drach J; Böhmig GA Transplantation; 2010 Jun; 89(11):1385-90. PubMed ID: 20335829 [TBL] [Abstract][Full Text] [Related]
20. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection. Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]